Approach

Summary

Licensing status

Publication and contact information

Drug delivery

Nonviral DNA nanoparticles for ocular gene therapy to treat Stargardt's disease

Mouse studies suggest nonviral DNA nanoparticles could be used for ocular gene therapy to help treat Stargardt's disease, a retinal degenerative disorder caused by mutations in ATP-binding cassette sub-family A member 4 (ABCA4; ABCR). In Abca4-deficient mice, nonviral DNA nanoparticles carrying human ABCA4 cDNA vectors and a photoreceptor-targeting promoter induced ABCA4 expression and decreased disease symptoms compared with saline. Next steps include testing the technology for delivery of a larger gene associated with vision disorders.

SciBX 5(34); doi:10.1038/scibx.2012.911
Published online Aug. 30, 2012

U.S. utility patent application filed; available for licensing

Han, Z. et al. J. Clin. Invest.; published online Aug. 13, 2012;
doi:10.1172/JCI64833
Contact: Muna I. Naash, The University of Oklahoma Health Sciences Center, Oklahoma City, Okla.
e-mail:

muna-naash@ouhsc.edu